BioSpace News Archive

Company to Host Conference Call with Study Chair on Monday, July 27 th at 4:30 pm ET

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency’s Committee for Medicin

Set to grow at a steady rate over the next few years, global mechanical ventilators market will witness generation of novel growth opportunities.

Privately held medical technology company Venock, Inc., headquartered in New York City, with the subsidiary Venock Medical GmbH in Munich, Germany, announced that it has expanded the design of its large bore venous closure system to also be effective at high pressure conditions for closure of large bore arterial perforations.

Getinge announces its intention to become a CO₂neutral company by 2025. The target will be reached by a stepwise approach in several areas and supports the company’s objective to contribute to a sustainable health care environmentally as well as socially.

Aleafia Health Inc. announced that Janssen Pharmaceuticals, Inc., has approved its wholly owned subsidiary, Canabo Medical Inc. as an administrator and prescriber of antidepressant SPRAVATO® nasal spray.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce call-in numbers and webcast link for the Annual General and Special Meeting of the shareholders of Blueberries Medical Corp. (the “AGM”).

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2020 financial results before the market open on Thursday, Aug. 6, 2020. In lieu of a call to discuss its quarterly results, Dicerna will host a virtual research and development (R&D) eve

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Laura Anthony to the Company’s Board of Directors, effective as of July 2, 2020.

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies WILMINGTON, Del.--( BUSINESS WIRE )-- AstraZeneca’s BREZTRI AEROSPHERE TM (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and Drug Ad